SCHEMBL22915967

SCHEMBL22915967

O=C(c1ccc(-c2ccccc2)cc1)N1CCc2[nH]cnc2C1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.50
HPGD P15428 1/20 0.50
NAMPT P43490 1/20 0.50
TRPV1 Q8NER1 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
SLC6A7 Q99884 3/20 0.48
ALDH1A1 P00352 2/20 0.48
TSHR P16473 1/20 0.48
HTR2B P41595 2/20 0.47
POLB P06746 2/20 0.47
MTHFD2 P13995 1/20 0.47
KDM4E B2RXH2 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GHSR Q92847 1/20 0.45
CDK4 P11802 2/20 0.45
CCND1 P24385 2/20 0.45
TACR3 P29371 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22915890 0.92 KDM4E (0.47) HPGDNAMPTMTHFD2KDM4E
SCHEMBL22915971 0.90 SLC6A7 (0.52) MAPK1HPGDNAMPTMEN1KMT2A
SCHEMBL22915970 0.85 POLB (0.55) HPGDNAMPTMEN1KMT2ASLC6A7
SCHEMBL24062095 0.85 NAMPT (0.47) HPGDNAMPTKMT2ASLC6A7ALDH1A1
SCHEMBL22915948 0.85 NAMPT (0.60) NAMPTHTR2BKDM4EL3MBTL1CDK4
Oxalic Acid SCHEMBL6423881 0.84 NAMPT (0.44) HPGDNAMPTMEN1KMT2ASLC6A7
SCHEMBL12321214 0.83 MTHFD2 (0.61) MAPK1HPGDNAMPTTRPV1MEN1
SCHEMBL22915886 0.83 NAMPT (0.51) HPGDNAMPTMEN1KMT2AALDH1A1
SCHEMBL20214421 0.82 NAMPT (0.56) HPGDNAMPTMTHFD2KDM4ECDK4
SCHEMBL22915934 0.81 HPGD (0.51) HPGDNAMPTSLC6A7ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186572-B2 Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2021-11-30 US disclosed
EP-3548613-B1 BACTERIAL GLUTAMINYL CYCLASE INHIBITORS AND USE THEREOF IN THE TREATMENT OF PERIODONTITIS FRAUNHOFER GES FORSCHUNG (DE) 2021-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11186572-B2 Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis GMPS, QPCT, GLS MAPK1 2638/4885HPGD 606/4885NAMPT 1158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.